Jison Maria L, Munson Peter J, Barb Jennifer J, Suffredini Anthony F, Talwar Shefali, Logun Carolea, Raghavachari Nalini, Beigel John H, Shelhamer James H, Danner Robert L, Gladwin Mark T
Critical Care Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 2004 Jul 1;104(1):270-80. doi: 10.1182/blood-2003-08-2760. Epub 2004 Mar 18.
In sickle cell disease, deoxygenation of intra-erythrocytic hemoglobin S leads to hemoglobin polymerization, erythrocyte rigidity, hemolysis, and microvascular occlusion. Ischemia-reperfusion injury, plasma hemoglobin-mediated nitric oxide consumption, and free radical generation activate systemic inflammatory responses. To characterize the role of circulating leukocytes in sickle cell pathogenesis we performed global transcriptional analysis of blood mononuclear cells from 27 patients in steady-state sickle cell disease (10 patients treated and 17 patients untreated with hydroxyurea) compared with 13 control subjects. We used gender-specific gene expression to validate human microarray experiments. Patients with sickle cell disease demonstrated differential gene expression of 112 genes involved in heme metabolism, cell-cycle regulation, antioxidant and stress responses, inflammation, and angiogenesis. Inducible heme oxygenase-1 and downstream proteins biliverdin reductase and p21, a cyclin-dependent kinase, were up-regulated, potentially contributing to phenotypic heterogeneity and absence of atherosclerosis in patients with sickle cell disease despite endothelial dysfunction and vascular inflammation. Hydroxyurea therapy did not significantly affect leukocyte gene expression, suggesting that such therapy has limited direct anti-inflammatory activity beyond leukoreduction. Global transcriptional analysis of circulating leukocytes highlights the intense oxidant and inflammatory nature of steady-state sickle cell disease and provides insight into the broad compensatory responses to vascular injury.
在镰状细胞病中,红细胞内血红蛋白S的脱氧会导致血红蛋白聚合、红细胞僵硬、溶血和微血管阻塞。缺血再灌注损伤、血浆血红蛋白介导的一氧化氮消耗以及自由基生成会激活全身炎症反应。为了确定循环白细胞在镰状细胞病发病机制中的作用,我们对27例镰状细胞病稳态患者(10例接受羟基脲治疗,17例未接受羟基脲治疗)和13例对照受试者的血液单核细胞进行了全转录组分析。我们使用性别特异性基因表达来验证人类微阵列实验。镰状细胞病患者表现出112个参与血红素代谢、细胞周期调控、抗氧化和应激反应、炎症及血管生成的基因的差异表达。诱导型血红素加氧酶-1及其下游蛋白胆绿素还原酶和细胞周期蛋白依赖性激酶p21上调,这可能导致镰状细胞病患者尽管存在内皮功能障碍和血管炎症,但仍表现出表型异质性且无动脉粥样硬化。羟基脲治疗并未显著影响白细胞基因表达,这表明该治疗除了白细胞减少外,直接抗炎活性有限。对循环白细胞的全转录组分析突出了稳态镰状细胞病强烈的氧化和炎症本质,并为对血管损伤的广泛代偿反应提供了见解。